Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Operating Leases (2019 - 2025)

Plus Therapeutics has reported Operating Leases over the past 7 years, most recently at $15000.0 for Q4 2025.

  • Quarterly Operating Leases fell 51.61% to $15000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $15000.0 through Dec 2025, down 51.61% year-over-year, with the annual reading at $15000.0 for FY2025, 51.61% down from the prior year.
  • Operating Leases was $15000.0 for Q4 2025 at Plus Therapeutics, down from $31000.0 in the prior quarter.
  • Over five years, Operating Leases peaked at $530000.0 in Q2 2021 and troughed at $15000.0 in Q4 2025.
  • The 5-year median for Operating Leases is $136000.0 (2023), against an average of $186470.6.
  • Year-over-year, Operating Leases decreased 7.52% in 2021 and then tumbled 66.1% in 2024.
  • A 5-year view of Operating Leases shows it stood at $269000.0 in 2021, then plummeted by 47.58% to $141000.0 in 2022, then tumbled by 39.72% to $85000.0 in 2023, then crashed by 63.53% to $31000.0 in 2024, then plummeted by 51.61% to $15000.0 in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Operating Leases are $15000.0 (Q4 2025), $31000.0 (Q4 2024), and $40000.0 (Q3 2024).